Fatal cardiac event following initiation of risperidone therapy.
about
Special considerations in the treatment of patients with bipolar disorder and medical co-morbiditiesA current review of olanzapine's safety in the geriatric patient: from pre-clinical pharmacology to clinical data.Analysis of West Virginia medicaid claims data for the prevalence of medical conditions and use of drugs likely to cause QT prolongation in patients with schizophrenia.Antipsychotic agents and QT changes.The pharmacology and toxicology of atypical antipsychotic agents.A Comparative Study between Olanzapine and Risperidone Regarding Drug-Induced Electrocardiographic Changes.Comparative cardiovascular safety of risperidone and olanzapine, based on electrocardiographic parameters and blood pressure: a prospective open label observational study.New Generation Antipsychotic Drugs and QTc Interval Prolongation.Olanzapine induced Q-Tc shortening.Hidden cardiac lesions and psychotropic drugs as a possible cause of sudden death in psychiatric patients: a report of 14 cases and review of the literature.Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?Drug-induced block of cardiac HERG potassium channels and development of torsade de pointes arrhythmias: the case of antipsychotics.Cardiologic side effects of psychotropic drugs.Antipsychotic drugs and QTc prolongation: the potential role of CYP2D6 genetic polymorphism.Simultaneous determination of five antipsychotic drugs in rat plasma by high performance liquid chromatography with ultraviolet detection.May the best friend be an enemy if not recognized early: possible role of omega-3 against cardiovascular abnormalities due to antipsychotics in the treatment of autism.Unmet treatment needs in schizophrenia patients: is asenapine a potential therapeutic option?CYP2D6 genotyping for psychiatric patients treated with risperidone: considerations for cost-effectiveness studies.QTc interval, CYP2D6 and CYP2C9 genotypes and risperidone plasma concentrations.Cardiovascular side effects of novel antipsychotics.Bacterial degradation of risperidone and paliperidone in decomposing blood.Inhibition of cloned hERG potassium channels by risperidone and paliperidone.Determination of Chlorpromazine, Haloperidol, Levomepromazine, Olanzapine, Risperidone, and Sulpiride in Human Plasma by Liquid Chromatography/Tandem Mass Spectrometry (LC-MS/MS)
P2860
Q24806762-FE04BC12-97DC-42F0-80EA-1F2EB8BC0AA6Q30667146-F8164A01-B50C-4B9E-9FE0-672A5B2AC762Q30832167-8E49314B-0550-4BDF-9CDB-C1C93CA71064Q33877850-DC146E41-FF8A-4522-ABEB-9DCFEDDD1059Q34235349-8A24680F-FB6F-4D8C-BDB2-0194887ABE03Q34243053-E604CDA2-D9F8-4D69-A2FE-1C3978DEA108Q34247635-FE4142DF-C5AE-436E-97E6-08D6219B54F3Q34319695-AF8E797F-F02F-4F5E-8A54-0059513E400DQ34642834-A214B4BF-0291-4228-8AAB-099858F25903Q35738824-6FF13D5D-CAAC-435A-897D-0410400EDA9CQ35867252-418D67AC-896C-4765-9D2C-91DFD65FB408Q36048792-CDF9AFF6-72BF-43F9-89F5-AFE85E8751BAQ36077336-24C9FEB1-ED4E-40A1-9991-99DBBC03422BQ36725206-18549117-2B89-4D41-A989-6097E7DAF2BBQ37349894-6AB6D2BD-89B8-4F97-B1F4-05C67EBD4268Q37617083-8C710880-DBC2-4A3C-9A6B-8CBA33BA0929Q37896627-F9487FB8-D276-4A77-B2DB-EA8C1BD31578Q44624989-32CBC85D-D10C-4205-9236-41B6DF5F3A0CQ44983984-10532E33-0C55-4CCC-BEBE-4DF2CFC26E98Q45029832-FB09B523-5FB8-4088-949A-1ADBF0494AE8Q45206731-573219BD-B43E-4AB7-AEC6-2832F636511FQ48157337-14B7E5A1-3695-4F95-9443-D23C768D4978Q58770172-52DAABD8-F52E-4F0A-B05F-53D0F09207F5
P2860
Fatal cardiac event following initiation of risperidone therapy.
description
1997 nî lūn-bûn
@nan
1997年の論文
@ja
1997年論文
@yue
1997年論文
@zh-hant
1997年論文
@zh-hk
1997年論文
@zh-mo
1997年論文
@zh-tw
1997年论文
@wuu
1997年论文
@zh
1997年论文
@zh-cn
name
Fatal cardiac event following initiation of risperidone therapy.
@en
Fatal cardiac event following initiation of risperidone therapy.
@nl
type
label
Fatal cardiac event following initiation of risperidone therapy.
@en
Fatal cardiac event following initiation of risperidone therapy.
@nl
prefLabel
Fatal cardiac event following initiation of risperidone therapy.
@en
Fatal cardiac event following initiation of risperidone therapy.
@nl
P2860
P1476
Fatal cardiac event following initiation of risperidone therapy.
@en
P2093
J W Levenson
P2860
P304
P356
10.1177/106002809703100712
P407
P577
1997-07-01T00:00:00Z